Robotic Partial Cystectomy for Bladder Cancer: A Single-Institutional Pilot Study

Allaparthi, Satya; Rajan, Rajesh; Balaji, K.C.

doi:10.1089/end.2009.0367

Cited by 32 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, Allaparthi and his team concluded that their early study showed promise that SCRPC is technically feasible for select patients with bladder cancer and the procedure shows adequate short-term oncological results [22]. We had comparable results at our institution with SCRPC in three patients as well, with mean EBL, hospital stay and mean operative time all within satisfactory limits [32].…”

Section: Oncological Outcomesmentioning

confidence: 83%

“…Guru et al also performed SCRRC on twenty consecutive patients between 2005 and 2006 and concluded that the procedure can be performed safely for candidates for open cystectomy [21]. In 2010, Allaparthi et al reported on a consecutive cohort of three patients undergoing surgeon-controlled robotic partial cystectomy (SCRPC) for bladder cancer which expanded the scope of this exciting new treatment modaility [22].…”

Section: Bladder Cancermentioning

confidence: 99%

“…In effort to preserve healthy bladder tissue, Allaparthi et al published the first study of three patients undergoing SCRPC [22].At a median follow-up of 6 months, all three patients were alive and had no signs of recurrent or metastasis [22]. Therefore, Allaparthi and his team concluded that their early study showed promise that SCRPC is technically feasible for select patients with bladder cancer and the procedure shows adequate short-term oncological results [22].…”

Section: Oncological Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

The Emergence of Surgeon-Controlled Robotic Surgery in Urologic Oncology

Patel

Babbar

Hemal

2011

Indian J Surg Oncol

View full text Add to dashboard Cite

The rise of robotic surgery is transforming medicine. In many ways, urology has taken charge in pioneering a new era of minimally invasive surgery with the emergence of the robot. The unprecedented dissecting precision and the dynamic three-dimensional, high definition view of the surgical field are undoubtedly revolutionizing the field of urology. These unique attributes of robotic surgery confer enormous advantages in dealing with urooncological surgery. The robotic revolution began nearly a decade ago with surgeon-controlled robotic radical prostatectomy and has since expanded to include radical cystectomies and partial nephrectomies. There have been numerous landmark studies published showing that robotic surgery provides comparable oncological and functional outcomes against traditional open or laparoscopic surgery. As a result, it becomes exceedingly imperative that urologists and the oncological community remain up-todate regarding these developments and appreciate the oncological outcomes of surgeon-controlled robotic surgery. This review will assess the impact surgeon-controlled robotic surgery has had in the field of urologic oncology.

show abstract

Section: Oncological Outcomesmentioning

confidence: 83%

Section: Bladder Cancermentioning

confidence: 99%

Section: Oncological Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

The Emergence of Surgeon-Controlled Robotic Surgery in Urologic Oncology

Patel

Babbar

Hemal

2011

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…6 However, the largest, and more recent, study of UA to date reported more modest recurrence rates; 15% of patients with non-metastatic UA developed local recurrence, and this was usually after partial cystectomy. 1 However, there was no difference in survival rates between patients who underwent partial cystectomy versus radical cystectomy.…”

Section: Discussionmentioning

confidence: 99%

“…5 In 2010 Allaparthi's team published the successful short-term outcome of a patient with UA who underwent robotic PC (RPC). 6 Here we present the case of a patient with metastatic UA who underwent robotic PC who is alive with no evidence of disease recurrence or metastatic disease at 5 years.…”

Section: Introductionmentioning

confidence: 99%

The role of robotic partial cystectomy in a patient with metastatic primary adenocarcinoma of the bladder

Vasdev

Adshead

2015

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

Case Report AbstractTreatment of urachal adenocarcinoma (UA) of the urinary bladder has typically been with radical cystectomy (RC) but more conservative approaches are gaining popularity. Here we present the case of a female patient with metastatic primary bladder UA who was treated with robotic partial cystectomy (RPC) and adjuvant chemotherapy; she is alive with no evidence of disease recurrence or metastatic disease at 5 years. This case provides some of the longest follow-up after RPC to date thereby demonstrating that RPC is a safe and oncologically viable treatment for selected patients even several years after definitive treatment.Patients undergoing RPC benefit from the reduced morbidity associated with this less radical treatment whilst enjoying similarly successful oncological outcomes to RC.

show abstract